Aetna rolls out in-network protection for Zolgensma, different multimillion-dollar gene therapies
Aetna is launching a delegated community to cowl new gene therapies for uncommon ailments, the insurer introduced Thursday.
The Gene-Primarily based, Mobile and Different Revolutionary Therapies (GCIT) community, which might be included as a typical community for Aetna absolutely insured plans, offers members entry to over 75 suppliers and a scientific crew to information members and suppliers via the care course of.
The community will launch Jan. 1, 2022, and canopy three gene therapies—Luxturna, Spinraza and Zolgensma—for inherited retinal illness and spinal muscular atrophy.
“We’re making a differentiated supplier community that our clients can expertise as being caring, related and handy,” stated Richard Gentleman, govt director of nationwide companion technique at Aetna, in a assertion. “Our multi-pronged strategy encompasses security, member entry to cutting-edge therapies, and value administration to assist the medical and financial wants of our members and clients. It additionally paves the way in which for future FDA-approved gene therapies to be added rapidly and cost-effectively in order that we may also help extra folks obtain their greatest well being.”
The FDA has accepted 22 mobile and gene therapies so far, most for cancers and uncommon ailments. Some biotech corporations are working to develop gene therapies to focus on extra widespread situations, like diabetes, weight problems and Alzheimer’s.
Gene therapies can include sky-high worth tags. Zolgensma, a spinal muscular atrophy remedy and one of many three therapies lined in Aetna’s new community, is the costliest treatment within the U.S., coming in at $2.1 million per course of remedy.
RELATED: How CVS Well being is addressing the price of gene therapies
Aetna expects gene therapies so as to add $45 billion to healthcare prices between 2020 and 2024 if the FDA approves all different therapies presently within the pipeline.
“Gene remedy is poised for important development within the coming years, and the promise of sturdy enchancment for sufferers with difficult ailments is thrilling,” stated Joanne Armstrong, M.D., chief medical officer of the ladies’s well being and genomics division at CVS Well being. “But excessive prices related to these therapies proceed to pose a big problem. It’s due to this fact important that they’re delivered by highly-specialized suppliers in an setting that may present the affected person receiving the remedy a excessive potential of a profitable final result.”
The community can also be out there to self-insured plans. Aetna will present journey and lodging assist for members who need to journey 100 miles or extra to obtain remedy, the corporate stated.
The community gives a monetary safety program for CVS Caremark purchasers and Aetna plan sponsors who don’t have stop-loss insurance coverage. CVS Well being acquired Aetna in 2018 for $69 billion.
